Aprea Therapeutics, Inc.
APRE
$1.59
-$0.0324-2.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.96M | -13.51M | -12.93M | -12.72M | -14.29M |
| Total Depreciation and Amortization | 22.30K | 21.90K | 17.90K | 12.80K | 7.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 435.10K | 509.80K | 404.10K | 483.10K | 483.40K |
| Change in Net Operating Assets | -1.06M | -809.90K | -1.05M | -913.30K | 1.62M |
| Cash from Operations | -13.56M | -13.79M | -13.56M | -13.13M | -12.18M |
| Capital Expenditure | -15.50K | -22.70K | -108.60K | -101.10K | -93.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -15.50K | -22.70K | -108.60K | -101.10K | -93.10K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16.14M | 16.00M | 16.00M | 16.00M | 5.79M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.32M | -1.31M | -1.31M | -1.29M | -648.90K |
| Cash from Financing | 14.82M | 14.69M | 14.69M | 14.71M | 5.14M |
| Foreign Exchange rate Adjustments | -7.10K | 17.90K | -10.20K | -58.90K | -8.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.24M | 897.20K | 1.01M | 1.42M | -7.14M |